Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.13)
# 2,966
Out of 5,090 analysts
37
Total ratings
48.48%
Success rate
-5.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $40 | $21.93 | +82.40% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $19.92 | +226.31% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $916.31 | -0.69% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.87 | +650.67% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $228.71 | -2.93% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $71.71 | +24.11% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.15 | +133.10% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $12.48 | +84.37% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.60 | +131.21% | 2 | Dec 20, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $22.81 | +645.29% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.58 | +336.68% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $221.75 | -7.10% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.04 | +624.88% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.60 | +284.62% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $86.35 | -30.52% | 1 | Oct 5, 2022 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $21.93
Upside: +82.40%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $19.92
Upside: +226.31%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $916.31
Upside: -0.69%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.87
Upside: +650.67%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $228.71
Upside: -2.93%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $71.71
Upside: +24.11%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.15
Upside: +133.10%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $12.48
Upside: +84.37%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.60
Upside: +131.21%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $22.81
Upside: +645.29%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.58
Upside: +336.68%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $221.75
Upside: -7.10%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.04
Upside: +624.88%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.60
Upside: +284.62%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $86.35
Upside: -30.52%